» Articles » PMID: 12349937

Experimental and Theoretical Determination of Dosimetric Characteristics of IsoAid ADVANTAGE 125I Brachytherapy Source

Overview
Journal Med Phys
Specialty Biophysics
Date 2002 Sep 28
PMID 12349937
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

125I brachytherapy sources are being used for interstitial implants in tumor sites such as the prostate. Recently, the ADVANTAGE 125I, Model IAI-125, source became commercially available for interstitial brachytherapy treatment. Dosimetric characteristics (dose rate constant, radial dose function, and anisotropy function) of this source were experimentally and theoretically determined, following the AAPM Task Group 43 recommendations. Derivation of the dose rate constant was based on recent NIST WAFAC calibration performed in accordance with their 1999 standard. Measurements were performed in Solid Water phantom using LiF thermoluminescent dosimeters. The theoretical calculations were performed in both Solid Water and water using the PTRAN Monte Carlo code. The results indicated that a dose rate constant of the new source in water was 0.98 +/- 0.03 cGy h(-1) U(-1). The radial dose function of the new source was measured in Solid Water and calculated both in water and Solid Water at distances up to 10.0 cm. The anisotropy function, F(r, theta), of the new source was measured and calculated in Solid Water at distances of 2 cm, 3 cm, 5 cm, and 7 cm and also was calculated in water at distances ranging from 1 cm to 7 cm from the source. From the anisotropy function, the anisotropy factors and anisotropy constant were derived. The anisotropy constant of the ADVANTAGE 125I source in water was found to be 0.97 +/- 0.03. The dosimetric characteristics of this new source compared favorably with those from the Amersham Health Model 6711 source. Complete dosimetric parameters of the new source are presented in this paper.

Citing Articles

Development of GATE Monte Carlo Code for Simulation and Dosimetry of New I-125 Seeds in Eye Plaque Brachytherapy.

Taherparvar P, Fardi Z Nucl Med Mol Imaging. 2021; 55(2):86-95.

PMID: 33968275 PMC: 8053639. DOI: 10.1007/s13139-020-00680-5.


Monte Carlo calculations and experimental measurements of the TG-43U1-recommended dosimetric parameters of 125I (Model IR-Seed2) brachytherapy source.

Sheikholeslami S, Nedaie H, Sadeghi M, Pourbeigy H, Shahzadi S, Zehtabian M J Appl Clin Med Phys. 2016; 17(4):430-441.

PMID: 27455485 PMC: 5690036. DOI: 10.1120/jacmp.v17i4.6127.


Brachytherapy Using Elastin-Like Polypeptides with (131)I Inhibit Tumor Growth in Rabbits with VX2 Liver Tumor.

Liu X, Shen Y, Zhang X, Lin R, Jia Q, Chang Y Dig Dis Sci. 2016; 61(10):2921-2927.

PMID: 27295104 DOI: 10.1007/s10620-016-4212-4.


Comparison of TG-43 dosimetric parameters of brachytherapy sources obtained by three different versions of MCNP codes.

Zaker N, Zehtabian M, Sina S, Koontz C, S Meigooni A J Appl Clin Med Phys. 2016; 17(2):379-390.

PMID: 27074460 PMC: 5874963. DOI: 10.1120/jacmp.v17i2.5797.


A comparison study on various low energy sources in interstitial prostate brachytherapy.

Bakhshabadi M, Ghorbani M, Khosroabadi M, Knaup C, S Meigooni A J Contemp Brachytherapy. 2016; 8(1):74-81.

PMID: 26985200 PMC: 4793066. DOI: 10.5114/jcb.2016.57708.